- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: Language delay.
Displaying page 1 of 1.
EudraCT Number: 2016-000222-19 | Sponsor Protocol Number: H2020-PHC-18-2015-667224 | Start Date*: 2017-08-02 | ||||||||||||||||
Sponsor Name:University Hospital Tuebingen | ||||||||||||||||||
Full Title: Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome – a blinded randomized placebo-controlled parallel group multicenter trial for superiori... | ||||||||||||||||||
Medical condition: Perinatal Asphyxia, hypoxic-ischemic brain injury | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing) FI (Trial now transitioned) EE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) PT (Prematurely Ended) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001466-42 | Sponsor Protocol Number: 17-HPNCL-02 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Fondation Lenval - Hôpitaux Pédiatriques de Nice CHULENVAL | |||||||||||||
Full Title: EFFECTIVENESS OF INTRANASAL DEXMEDETOMIDINE FOR SEDATED AUDITORY BRAINSTEM RESPONSE TESTING | |||||||||||||
Medical condition: Child requiring auditory evaluation in a context of suspicion of deafness, language delay, overall developmental delay, risk factors for hearing loss. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003972-64 | Sponsor Protocol Number: 2015-09 | Start Date*: 2019-07-02 |
Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE | ||
Full Title: Plasma and tissue pharmacokinetics of amikacin administrated by dressing impregnated in burns patients | ||
Medical condition: burns patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-004057-23 | Sponsor Protocol Number: 2021-12945 | Start Date*: 2022-02-28 |
Sponsor Name:Radboudumc | ||
Full Title: Ethanol submandibular duct ligation for drooling in children with neurodisabilities | ||
Medical condition: Drooling or sialorrhea | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003400-39 | Sponsor Protocol Number: NGLU-CL02 | Start Date*: 2014-07-15 | ||||||||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously | ||||||||||||||||||
Medical condition: Mucopolysaccharidosis III, type B (MPS IIIB), Sanfilippo B | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Temporarily Halted) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-000891-85 | Sponsor Protocol Number: 190-203 | Start Date*: 2017-09-05 | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc | |||||||||||||
Full Title: A Phase 2, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Pediatric Patients < 18 years of age with CLN2 Disease | |||||||||||||
Medical condition: Neuronal Ceroid Lipofuscinosis type 2 (CLN2) disease | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002574-31 | Sponsor Protocol Number: US1/001/10(TDU13600) | Start Date*: 2013-10-25 | ||||||||||||||||
Sponsor Name:sanofi-aventis recherche & développement | ||||||||||||||||||
Full Title: A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR421869, Administered to Patients with Retinitis Pigmentosa Associated with Usher Syndrome Type 1B | ||||||||||||||||||
Medical condition: Retinitis Pigmentosa, associated with Ushers Syndrome Type 1B. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000659-42 | Sponsor Protocol Number: TN-22 | Start Date*: 2019-03-12 |
Sponsor Name:TrialNet Coordinating Center | ||
Full Title: HYDROXYCHLOROQUINE FOR PREVENTION OF ABNORMAL GLUCOSE TOLERANCE AND DIABETES IN INDIVIDUALS AT-RISK FOR TYPE 1 DIABETES MELLITUS | ||
Medical condition: individuals at-risk for type 1 diabetes mellitus (T1D) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Completed) FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001109-22 | Sponsor Protocol Number: PBGM01-001 | Start Date*: Information not available in EudraCT |
Sponsor Name:Passage Bio, Inc. | ||
Full Title: A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Su... | ||
Medical condition: GM1 gangliosidosis (GM1) is an autosomal recessive disorder that results from mutations in the human galactosidase beta 1 gene (GLB1), which encodes beta-galactosidase (β-gal). | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002548-26 | Sponsor Protocol Number: 0139 | Start Date*: 2020-12-16 | ||||||||||||||||
Sponsor Name:Royal College of Surgeons in Irlenad | ||||||||||||||||||
Full Title: Can Pentoxifylline improve long-term outcomes in preterm infants with late-onset sepsis or necrotizing enterocolitis? A pragmatic, randomised, placebo controlled trial | ||||||||||||||||||
Medical condition: Late onset sepsis & necrotising enterocolitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: IE (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000105-53 | Sponsor Protocol Number: 17P-FU-004 | Start Date*: 2011-04-20 |
Sponsor Name:Hologic, Inc. | ||
Full Title: Estudio prospectivo, de seguimiento, de niños de 23 a 25 meses, nacidos de madres que recibieron Caproato de Hidroxiprogesterona inyectable, 250 mg/ml o vehículo, para la prevención del parto prema... | ||
Medical condition: Este es un estudio prospectivo, de seguimiento, diseñado para aportar una evaluación del desarrollo de niños nacidos de madres que participaron en el ensayo de eficacia de 17P | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004016-11 | Sponsor Protocol Number: 2305 | Start Date*: 2016-06-30 | ||||||||||||||||
Sponsor Name:University of Bristol | ||||||||||||||||||
Full Title: What is the clinical and cost effectiveness of benzocaine/phenazone ear drops for reducing antibiotic consumption and ear pain in children aged between 6 months and 10 years presenting to primary c... | ||||||||||||||||||
Medical condition: Acute otitis media | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001530-10 | Sponsor Protocol Number: NoPac01 | Start Date*: 2017-02-20 | |||||||||||
Sponsor Name:Royal Devon & Exeter NHS Foundation Trust | |||||||||||||
Full Title: A randomised controlled trial of topical intranasal tranexamic acid versus placebo to reduce the need for nasal packing in patients presenting to the Emergency Department with spontaneous epistaxis. | |||||||||||||
Medical condition: Atraumatic epistaxis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004411-11 | Sponsor Protocol Number: NeoTreme | Start Date*: 2023-05-03 | |||||||||||
Sponsor Name: University Hospital Schleswig-Holstein, Campus Lübeck | |||||||||||||
Full Title: Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (NeoTreme) | |||||||||||||
Medical condition: Intrahepatic cholangiocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006295-37 | Sponsor Protocol Number: 06/AN/04 | Start Date*: 2007-04-05 | |||||||||||
Sponsor Name:NHS Greater Glasgow & Clyde | |||||||||||||
Full Title: A multi-site RCT comparing regional and general anaesthesia for effects on neurodevelopmental outcome and apnoea in infants. | |||||||||||||
Medical condition: Inguinal hernia in neonates and infants | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000453-41 | Sponsor Protocol Number: BMBF-Fz01KG1602 | Start Date*: 2018-05-29 | |||||||||||||||||||||||||||||||
Sponsor Name:University Hospital Tuebingen | |||||||||||||||||||||||||||||||||
Full Title: Effects of closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C) on outcome of extremely preterm infants – a randomized controlled parallel group multicenter trial for safety... | |||||||||||||||||||||||||||||||||
Medical condition: Extremely low gestational age neonates (ELGANs), i.e. those who are born at <28 weeks gestation and who uniformly suffer from intermittent hypoxemic episodes. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013616-12 | Sponsor Protocol Number: R096769PRE3008 | Start Date*: 2010-04-12 | |||||||||||
Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Dapoxetine in Men With Premature Ejaculation and Concomitant Erectile Dy... | |||||||||||||
Medical condition: Premature ejaculation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004909-27 | Sponsor Protocol Number: DNLI-E-0002 | Start Date*: 2020-07-22 | |||||||||||
Sponsor Name:Denali Therapeutics Inc. | |||||||||||||
Full Title: A PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DNL310 IN PEDIATRIC SUBJECTS WITH HUNTER SYNDROME | |||||||||||||
Medical condition: Hunter Syndrome (Mucopolysaccharidosis Type II [MPS II]) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000287-42 | Sponsor Protocol Number: I15015 | Start Date*: 2016-05-18 | |||||||||||
Sponsor Name:CHU de Limoges | |||||||||||||
Full Title: A Multicentre Open label Phase II study of Daratumumab in AL Amyloidosis Patients not in VGPR or Better | |||||||||||||
Medical condition: AL Amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000567-26 | Sponsor Protocol Number: 2010-021883-14 | Start Date*: 2013-01-31 | |||||||||||
Sponsor Name:Radboud University Medical Centre Nijmegen | |||||||||||||
Full Title: A randomized double-blind, placebo-controlled study of risperidone in the treatment of DSM-IV-TR conduct disorder in children and adolescents. | |||||||||||||
Medical condition: Conduct Disorder DSM-IV-TR; 312.8x¸ APA, 2000 | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
